Prof Gerard Zalcman speaks to ecancer at the ESMO Congress 2023 to discuss a study aimed at evaluating the feasibility and safety of administering a radiotherapy boost of up to 74 Gy to patients with inoperable stage III non-small cell lung cancer.
The study was based on the patients' early response to on-treatment FDG-PET/CT at 42 Gy of radiochemotherapy.
Prof Zalcman concludes by discussing the results of the study which found boost at 74 Gy based on interim FDG-PET is feasible and safe during thoracic radio-chemotherapy, without acute or late toxicity.